Universe Pharmaceuticals INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation China
Business Address 265 JINGJIU AVENUE, JI'AN, JIANGXI, F4, 343100
Mailing Address 265 JINGJIU AVENUE, JI'AN, JIANGXI, F4, 343100
Phone 86-0796-8403309
Fiscal Year End 0930
EIN 000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 11, 2026 | View on SEC |
| 20-F Foreign company annual report | January 29, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 7, 2026 | View on SEC |
| 6-K Foreign company current report | September 3, 2025 | View on SEC |
| 6-K Foreign company current report | August 26, 2025 | View on SEC |
| 6-K Foreign company current report | July 29, 2025 | View on SEC |
| 6-K Foreign company current report | July 3, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | May 15, 2025 | View on SEC |
| 20-F Foreign company annual report | April 29, 2025 | View on SEC |
Annual Reports
20-F January 29, 2026
- Total revenue reached $125.8 million in FY2023, marking a 5.2% increase from FY2022.
- Successfully launched two new TCM derivative products and expanded its distribution network into three new provinces.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.